BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, ...

SAN DIEGO, March 25, 2025 /PRNewswire/ — Adcentrx Therapeutics (“Adcentrx”), a clinical-stage biotechnology company ... stage STEAP1 ADC, and a poster presentation on ADRX-0134, its ...

CHICAGO, March 25, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC ...

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek ...

MAIA Biotechnology, Inc., (NYSE American ... a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking ...

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech ... today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic ...

CHICAGO, March 25, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American ... detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the ...

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech ... today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic ...

Poster highlights potential predictive biomarker ... of-care regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused ...